Percheron Therapeutics Limited (ASX:PER)

Percheron Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Operating Revenue	-	-	1.96	-	-
Other Revenue	1.8	2.97	-	1.78	0.58
Revenue	1.8	2.97	1.96	1.78	0.58
Revenue Growth (YoY)	-39.32%	51.07%	10.51%	207.72%	-13.56%
Cost of Revenue	0.17	0.06	0.03	0.07	0.11
Gross Profit	1.63	2.91	1.93	1.71	0.47
Selling, General & Admin	4.15	3.84	2.84	2.8	2.18
Research & Development	10.77	10.7	10.16	4.54	4.91
Operating Expenses	16.54	14.82	13.31	7.55	8.57
Operating Income	-14.91	-11.92	-11.38	-5.83	-8.11
Interest Expense	-0.01	-0	-0.01	-0.01	-0.01
Interest & Investment Income	-	-	-	0.03	0
Currency Exchange Gain (Loss)	-	-	0.01	-0	-0
EBT Excluding Unusual Items	-14.92	-11.92	-11.38	-5.81	-8.12
Other Unusual Items	-	-	-	-	0.05
Pretax Income	-14.92	-11.92	-11.38	-5.81	-8.06
Net Income	-14.92	-11.92	-11.38	-5.81	-8.06
Net Income to Common	-14.92	-11.92	-11.38	-5.81	-8.06
Shares Outstanding (Basic)	1,024	881	669	634	541
Shares Outstanding (Diluted)	1,024	881	669	634	541
Shares Change (YoY)	16.22%	31.74%	5.45%	17.25%	18.68%
EPS (Basic)	-0.01	-0.01	-0.02	-0.01	-0.01
EPS (Diluted)	-0.01	-0.01	-0.02	-0.01	-0.01
Free Cash Flow	-15.65	-10.12	-8.18	-7.81	-5.84
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.01	-0.01
Gross Margin	90.71%	97.91%	98.32%	96.31%	80.91%
Operating Margin	-827.68%	-401.45%	-579.21%	-328.10%	-1402.91%
Profit Margin	-828.51%	-401.57%	-579.19%	-326.89%	-1395.14%
Free Cash Flow Margin	-868.97%	-340.93%	-416.36%	-439.23%	-1011.23%
EBITDA	-14.84	-11.84	-11.37	-5.83	-8.1
D&A For EBITDA	0.07	0.08	0.01	0.01	0.01
EBIT	-14.91	-11.92	-11.38	-5.83	-8.11
Revenue as Reported	-	-	-	1.81	0.64

Source: S&P Global Market Intelligence. Standard template. Financial Sources.